Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.49 USD | +3.22% | -1.54% | -28.39% |
Sales 2024 * | 40.01M 3.34B | Sales 2025 * | 97.75M 8.15B | Capitalization | 162M 13.5B |
---|---|---|---|---|---|
Net income 2024 * | -58M -4.84B | Net income 2025 * | -26M -2.17B | EV / Sales 2024 * | 4.05 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.66 x |
P/E ratio 2024 * |
-3.04
x | P/E ratio 2025 * |
-7.28
x | Employees | 136 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.93% |
Latest transcript on scPharmaceuticals Inc.
1 day | +3.22% | ||
1 week | -1.54% | ||
Current month | -10.56% | ||
1 month | -8.55% | ||
3 months | -15.60% | ||
6 months | -20.81% | ||
Current year | -28.39% |
Managers | Title | Age | Since |
---|---|---|---|
John Tucker
CEO | Chief Executive Officer | 61 | 01/17/01 |
Rachael Nokes
DFI | Director of Finance/CFO | 49 | 01/14/01 |
John Mohr
CTO | Chief Tech/Sci/R&D Officer | - | 01/17/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 01/14/01 | |
Klaus Veitinger
BRD | Director/Board Member | 62 | 21/17/21 |
John Tucker
CEO | Chief Executive Officer | 61 | 01/17/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +2.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 4.49 | +3.22% | 119,733 |
25/24/25 | 4.35 | -3.33% | 187,355 |
24/24/24 | 4.5 | -2.39% | 92,041 |
23/24/23 | 4.61 | +0.88% | 85,259 |
22/24/22 | 4.57 | +0.22% | 113,931 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.39% | 162M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- SCPH Stock